Canlyniadau Chwilio am Awdur :: APM

1

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition gan Maud Condomines, Jon Arnason, Reuben Benjamin, Gertrude Gunset, Jason Plotkin, Michel Sadelain

Cyhoeddwyd 2015

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
2

Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025 gan Gena Kanas, Wenzhen Ge, Ruben G.W. Quek, Katie Keeven, Knar Nersesyan, Jon Arnason

Cyhoeddwyd 2021

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
3

Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years gan Alison M. Schram, Paige Comstock, Meghan Campo, Daniel Gorovets, Ann Mullally, Kelly Bodio, Jon Arnason, Nancy Berliner

Cyhoeddwyd 2015

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
4

Assessing Unwanted Variations in Rheumatology Clinic Previsit Rooming gan Edmond Ramly, Brad Stroik, Diane Lauver, Heather M. Johnson, Patrick E. McBride, Kristin Lewicki, Jón Árnason, Christie M. Bartels

Cyhoeddwyd 2018

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
5

Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease gan Katharina Lahl, Christoph Loddenkemper, Cathy E. Drouin, Jennifer Freyer, Jon Arnason, Gérard Eberl, Alf Hamann, Hermann Wagner, Jochen Huehn, Tim Sparwasser

Cyhoeddwyd 2007

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
6

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma gan Jeremy S. Abramson, Jon Arnason, Ann S. LaCasce, Robert Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ephraim P. Hochberg, Celeste M. Bello

Cyhoeddwyd 2019

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
7

Lenalidomide enhances anti-myeloma cellular immunity gan Katarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, Dina Stroopinsky, Turner Kufe, Baldev Vasir, Jon Arnason, D. Tzachanis, Jeffrey I. Zwicker, Robin Joyce, James D. Levine, Kenneth C. Anderson, Donald Küfe, David Avigan

Cyhoeddwyd 2012

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
8

$Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL$

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL gan Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, K. OGASAWARA, Jerill Thorpe, William G. Wierda

Cyhoeddwyd 2021

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
9

MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells gan Dina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, Heidi Mills, Li Yin, Hasan Rajabi, Baldev Vasir, Turner Kufe, Katarina Luptakova, Jon Arnason, Caterina Nardella, James D. Levine, Robin Joyce, Ilene Galinsky, Yoram Reiter, Richard M. Stone, Pier Paolo Pandolfi, Donald Küfe, David Avigan

Cyhoeddwyd 2013

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
10

$Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study$

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study gan Matthew S. Davids, Haesook T. Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur, Jeffrey Hellman, Josie Bazemore, Hari P. Miskin, Peter Sportelli, Laura Stampleman, Rodrigo Maegawa, Jens Rueter, Adam Boruchov, Jon Arnason, Caron A. Jacobson, Eric D. Jacobsen, David C. Fisher, Jennifer R. Brown

Cyhoeddwyd 2018

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
11

$Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)$

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL) gan Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostić, Yeonhee Kim, K. OGASAWARA, Christine Dehner, Tanya Siddiqi

Cyhoeddwyd 2021

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
12

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study gan Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, K. OGASAWARA, Manali Kamdar

Cyhoeddwyd 2022

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
13

$Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001$

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001 gan Maria Lia Palomba, Leo I. Gordon, Tanya Siddiqi, Jeremy S. Abramson, Manali Kamdar, Matthew A. Lunning, David G. Maloney, Charalambos Andreadis, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Scott R. Solomon, Thalia A. Farazi, Jacob Garcia, Christine Dehner, K. OGASAWARA, Jie Gao, Michael Wang

Cyhoeddwyd 2020

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
14

$Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas$

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas gan Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, D. Li, Yeonhee Kim, Tanya Siddiqi

Cyhoeddwyd 2019

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
15

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity gan Benjamin L. Lampson, Siddha Kasar, Tiago R. Matos, Elizabeth A. Morgan, Laura Z. Rassenti, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Caron A. Jacobson, Philippe Armand, Jeremy S. Abramson, Jon Arnason, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John Hanna, Jerome Ritz, Haesook T. Kim, Jennifer R. Brown

Cyhoeddwyd 2016

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
16

$Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy$

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patie... gan Rajat Bannerji, John N. Allan, Jon Arnason, Jennifer R. Brown, Ranjana H. Advani, Stephen M. Ansell, Susan O’Brien, Johannes Duell, Peter Martin, Robin Joyce, Jingjin Li, Dina M. Flink, Min Zhu, David M. Weinreich, George D. Yancopoulos, Andres Sirulnik, Aafia Chaudhry, Srikanth R. Ambati, Max S. Topp

Cyhoeddwyd 2020

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
17

$Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial$

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort i... gan Rajat Bannerji, Jon Arnason, Ranjana H. Advani, Jennifer R. Brown, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Susan O’Brien, Julio C. Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L. Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R. Ambati, Aafia Chaudhry, Israel Lowy, Max S. Topp

Cyhoeddwyd 2022

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
18

$Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial$

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial gan Jennifer R. Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina D. Wagner‐Johnston, Oliver G. Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Gabrail, Siddhartha Ganguly, Sikander Ailawadhi, Siddha Kasar, Arnon P. Kater, Jeanette K. Doorduijn, Lei Gao, Joanne Lager, Bin Wu, Coumaran Égile, Marie José Kersten

Cyhoeddwyd 2018

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
19

$Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study$

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autolo... gan Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glaß, Veronika Bachanová, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco J. Hernandez‐Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, David G. Maloney, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Lara Stepan, K. OGASAWARA, Timothy R. Mack, Jeremy S. Abramson

Cyhoeddwyd 2021

Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn:
20

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia gan Athalia R. Pyzer, Dina Stroopinsky, Hasan Rajabi, Abigail Washington, Ashujit Tagde, Maxwell Coll, Jacqueline Fung, Mary Paty Bryant, Leandra Cole, Kristen Palmer, Poorvi Somaiya, Rebecca Karp Leaf, Myrna Nahas, Arie Apel, Salvia Jain, Malgorzata McMasters, Lourdes M. Mendez, James D. Levine, Robin Joyce, Jon Arnason, Pier Paolo Pandolfi, Donald Küfe, Jacalyn Rosenblatt, David Avigan

Cyhoeddwyd 2017

Cael y testun llawn Cael y testun llawn
Artigo

Ychwanegu at ffefrynnau

Wedi'i Gadw mewn: